Current concepts on pulmonary host defense mechanisms in children

Current Opinion in Pediatrics

Volumn 12, Issue 3, 2000, Pages 187-193

  Wilmott, Robert W ^a   Khurana Hershey, Gurjit ^a   Stark, James M ^b  

^a UNIVERSITY OF CINCINNATI   (United States)

^b University of Missouri   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; CHEMOTACTIC FACTOR; COLONY STIMULATING FACTOR 1; COMPLEMENT; CYTOKINE; DEFENSIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INTERLEUKIN 1; INTERLEUKIN 6; LACTOFERRIN; PLATELET DERIVED GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA;

ANTIBODY RESPONSE; ANTIMICROBIAL ACTIVITY; ARTICLE; CELLULAR IMMUNITY; CYTOKINE RELEASE; HOST RESISTANCE; HUMORAL IMMUNITY; IMMUNOMODULATION; LUNG ALVEOLUS MACROPHAGE; LUNG DISEASE; LYMPHOCYTE; MACROPHAGE; MICROORGANISM; NEUTROPHIL; PRIORITY JOURNAL; RESPIRATORY SYSTEM;

ANIMALS; ANTIBODY FORMATION; ANTIBODY SPECIFICITY; BLOOD PROTEINS; CHILD; HUMANS; IMMUNITY, CELLULAR; LUNG; RESPIRATORY TRACT INFECTIONS;

EID: 0034112333     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008480-200006000-00002     Document Type: Article

References (78)

1. 1 Mason RJ, Greene K, Voelker DR: Surfactant protein A and surfactant protein D in health and disease. Amer J Physiol Lung 1998, 275:1-133.
2. 2 LeVine AM, Bruno MD, Huelsman KM, Ross GF, Whitsett JA, Korfhagen TR: Surfactant protein A-deficient mice are susceptible to group B streptococcal infection. J Immunol 1997, 158:4336-4340.
3. 3 LeVine AM, Kurak KE, Bruno MD, Stark JM, Whitsett JA, Korfhagen TR: Surfactant protein-A-deficient mice are susceptible to Pseudomonas aeruginosa infection. Am J Resp Cell Mol Biol 1998, 19:700-708.
4. 4 LeVine AM, Gwozdz J, Stark J, Bruno M, Whitsett J, Korfhagen T: Surfactant protein-A enhances respiratory syncytial virus clearance in vivo. J Clin Invest 1999, 103:1015-1021. Mice lacking pulmonary surfactant protein-A were infected with respiratory syncytial virus by intratracheal instillation. Pulmonary infiltration was more severe in the SPA -/-mice compared with controls, and was associated with an increased number of RSV plaque-forming units in lung homogenates. Concentrations of TNFα and IL-6 were increased in the SP-A knock-out mice; they were noted to have decreased superoxide and hydrogen peroxide generation. Co-administration of exogenous SP-A reduced viral titers and inflammatory cells in the SP-A -/-mice. These findings demonstrate the host defense rote of SP-A in vivo.
5. 5 Harrod KS, Trapnell BC, Otake K, Korfhagen TR, Whitsett JA: SP-A enhances viral clearance and inhibits inflammation after pulmonary adenoviral infection. Am J Physiol 1999, 277:580-588. SP-A -/-mice were infected by intratracheal injection with replication-deficient recombinant adenovirus containing a luciferase marker gene. Lung inflammation was markedly increased in the SP-A -/-mice compared with wild-type mice and was associated with increased hemorrhage and epithelial cell injury. Co-administration of purified human SP-A reduced adenoviral-induced lung inflammation in the SP-A -/-mice. This study shows that SP-A enhances viral clearance and inhibits lung inflammation during pulmonary viral infection.
6. 6 Whitsett JA: Role of collectins in the modulation of pulmonary host defense and inflammation. Pediatr Pulmonol 1999, 19 (suppl):154.
7. 7 Crouch EC: Collectins and pulmonary host defense. Am J Resp Cell Mol Biol 1998, 19:177-201.
8. 8 Rosseau S, Hammerl P, Maus U, Gunther A, Seeger W, Grimminger F, et al: Surfactant protein A down-regulates proinflammatory cytokine production evoked by Candida albicans in human alveolar macrophages and monocytes. J Immunol 1999, 163:4495-4502. The effect of recombinant human SP-A and natural canine SP-A was studied on the human alveolar macrophage response to Candida albicans. Both forms of SP-A reduced the expression of TNFα, IL-1β, Mip-1α, and MCP-1 in a dose-dependent manner. SP-A did not affect baseline liberation of these cytokines. Release of the anti-inflammatory cytokines IL-1 receptor antagonist and IL-6 was not inhibited by SP-A. The effect of SP-A required internalization by the mononuclear phagocytes, suggesting that it has an effect on the expression of pro-inflammatory cytokine synthesis at the transcriptional level.
9. 9 Kuan SF, Rust K, Crouch E: Interactions of surfactant protein D with bacterial lipopolysaccharides. Surfactant protein D is an Escherichia coil-binding protein in bronchoalveolar lavage. J Clin Invest 1992, 90:97-1066.
10. 10 Hickling TP, Bright H, Wing K, Gower D, Martin SL, Sim RB, et al.: A recombinant trimeric surfactant protein D carbohydrate recognition domain inhibits respiratory syncytial virus infection in vitro and in vivo. Eur J Immunol 1999, 29:3478-3484. The effects of recombinant trimeric SPD lectin domains was studied in relation to the binding of RSV-G protein. The study was performed by infection of monolayers of HEP-2C cells and in vivo infections in BALB/c mice. Full-length and recombinant SP-D bound to RSV-G protein in a concentration-dependent manner. Binding was inhibited by EDTA and mannan, indicating that binding occurs via carbohydrate recognition domain of SP-D. Recombinant SPD inhibited RSV infectivity in cell culture in a dose-dependent manner. Intranasal administration of recombinant SPD to RSV-infected mice inhibited replication in the lungs and reduced levels of virus by 80%.
11. 11 Hartshorn KL, Crouch E, White MR, Colamussi ML, Kakkanatt A, Tauber B, et al: Pulmonary surfactant proteins A and D enhance neutrophil uptake of bacteria. Am J Physiol 1998, 274:L958-L969.
12. 12 Williams MD, Wright JR, March KL, Martin WJ: Human surfactant protein A enhances attachment of Pneumocystis carinii to rat alveolar macrophages. Am J Resp Cell Mol Biol 1996, 14:232-238.
13. 13 Restrepo CI, Dong Q, Savov J, Mariencheck WI, Wright JR: Surfactant protein D stimulates phagocytosis of Pseudomonas aeruginosa by alveolar macrophages. Am J Resp Cell Mol Biol 1999, 21:576-585. The effects of SP-D on uptake of P. aeruginosa by rat alveolar macrophages was studied by fluorescence and electron microscopy. SP-D bound to live P. aeruginosa, and in vitro killing assays demonstrated that macrophage-mediated killing of one of six strains of P. aeruginosa was modestly enhanced by SP-D.
14. 14 Ferguson JS, Voelker DR, McCormack FX, Schlesinger LS: Surfactant protein D binds to Mycobacterium tuberculosis bacilli and lipoarabinomannan via carbohydrate-lectin interactions resulting in reduced phagocytosis of the bacteria by macrophages. J Immunol 1999, 163:312-321. These authors demonstrated that specific binding of SP-D to M. tuberculosis was saturable, calcium dependent, and inhibitable by carbohydrates. Incubation of M. tuberculosis with SP-D led to agglutination of the bacteria. Incubation of M. tuberculosis with subagglutinating concentrations of SP-D led to reduced adherence of the bacteria to macrophages, whereas adherence was increased by incubation with SP-A.
15. 15 Ganz T, Lehrer RI: Antimicrobial peptides of vertebrates. Curr Opin Immunol 1998, 10:41-44.
16. 16 Diamond G, Zasloff M, Eck H, Brasseur M, Maloy WL, Bevins CL: Tracheal antimicrobial peptide, a cysteine-rich peptide from mammalian tracheal mucosa: peptide isolation and cloning of a cDNA. Proc Natl Acad Sci 1991, 88:3952-3956.
17. 17 Huttner KM, Bevins CL: Antimicrobial peptides as mediators of epithelial host defense. Pediatr Res 1999, 45:785-794.
18. 18 Yang D, Chertov O, Bykovskaia SN, Chen Q, Buffo MJ, Shogan J, et al.: Beta-defensins: linking innate and adaptive immunity through dendritic and T cell CCR6. Science 1999, 286:525-528. This important study showed the human beta-defensins are chemotatic for immature dendritic cells and memory T cells. When these cells were stably transfected with human chemokine receptor 6 (CCR6), which they usually express, they demonstrated selective chemotaxis to human beta-defensin. This induced chemotaxis was sensitive to pertussis toxin and inhibited by antibodies to CCR6. The binding of a labeled ligand to CCR6 was competitively displaced by beta-defensin. These results suggest that β-defensins may facilitate specific immune response by recruiting dendritic and T cells to the sites of infection by interacting with CCR6.
19. 19 Smith JJ, Travis SM, Greenberg EP, Welsh MJ: Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. Cell 1996, 85:229-236.
20. 20 Zabner J, Smith JJ, Karp PH, Widdicombe JH, Welsh MJ: Loss of CFTR chloride channels alters salt absorption by cystic fibrosis airway epithelia in vitro. Mol Cell Biol 1998, 2:397-403.
21. 21 Bals R, Wang X, Zasloff M, Wilson JM: The peptide antibiotic LL-37/hCAP-18 is expressed in epithelia of the human lung where it has broad antimicrobial activity at the airway surface. Proc Natl Acad Sci 1998, 95:9541-9546.
22. 22 Bals R, Weiner DJ, Meegalla RL, Wilson JM: Transfer of a cathelicidin peptide antibiotic gene restores bacterial killing in a cystic fibrosis xenograft model. J Clin Invest 1999, 103:1113-1177. Airways surface fluid from cystic fibrosis airway xenografts does not kill P. aeruginosa or S. aureus. Cystic fibrosis xenografts were transfected with an adenovirus expressing the human cathelicidin LL-37/hCAP-18. Levels of the peptide were increased three-to fourfold over baseline by this treatment, and bacterial killing activity was restored to normal levels.
23. 23 Bals R, Weiner DJ, Moscioni AD, Meegalla RL, Wilson JM: Augmentation of innate host defense by expression of a cathelicidin antimicrobial peptide. Infect Immun 1999, 67:6084-6099. To investigate overexpression of the antimicrobial peptide LL-37/hCPA-18 in the lungs, C57BI/6 mice received an adenoviral vector containing the cDNA for this peptide. Mice treated with the vector had a lower bacterial load and a reduced inflammatory response after pulmonary challenge with P. aeruginosa. Systemic expression of the vector by intravenous injection resulted in improved survival rates following intravenous injection of E. coli or lipopolysaccharide. This important study demonstrates that expression of an antimicrobial peptide by gene transfer results in augmentation of the innate immune response.
24. 24 Johnston CJ, Mango GW, Finkelstein JN, Stripp BR: Altered pulmonary response to hyperoxia in Clara cell secretory protein deficient mice. Amer J Respir Cell Mol Biol 1997, 17:147-155.
25. 25 Harrod KS, Mounday AD, Stripp BR, Whitsett JA: Clara cell secretory protein decreases lung inflammation after acute virus infection. Amer J Physiol-Lung 1998, 275:924-930. Clara cell secretory protein is a polypeptide synthesized and secreted by nonciliated bronchiolar epithelial cells. CCSP knock-out mice were exposed to a recombinant E1-and E3-deleted adenoviral vector containing the luciferase marker gene. Lung inflammation was markedly increased in the CCSP knock-out mice compared with wild-type controls and associated with an increased number of polymorphonuclear cell infiltrates and increased epithelial cell injury. This increased injury was associated with increased concentrations of IL-1β, TNFα, Mip-1α, and MCP-1. Adenoviral-mediated gene transfer was decreased in the knock-out mice compared with wild-type controls. This study indicates that CCSP modulates lung inflammation in response to viral infection.
26. 26 Ikegami M, Harrod KS, Whitsett JA, Jobe AH: CCSP deficiency does not alter surfactant homeostasis during adenoviral infection. Amer J Physiol Lung 1999, 277:983-987. The hypothesis that CCSP deficiency would influence surfactant metabolism after pulmonary infection was investigated. Surfactant pool sizes were studied before and 7 days after intratracheal administration of an adenovirus. The surfactant pool sizes were similar in the CCSP -/-and wild-type mice, and did not change in response to infection.
27. 27 Baveye S, Elass E, Mazurier J, Spik G, Legrand D: Lactoferrin: a multifunctional glycoprotein involved in the modulation of the inflammatory process. Clin Chem Lab Med 1999, 37:281-286. This paper reviews the activities of lactoferrin. Lactoferrin modulates the inflammatory response by inhibiting release of cytokines from monocytes and regulates in the proliferation differentiation of immune cells. Some of these activities are related to the ability of lactoferrin to bind LPS with high affinity and to prevent its binding to CD14.
28. 28 Elass-Rochard E, Legrand D, Salmon V, Roseanu A, Trif M, Tobias PS, et al: Lactoferrin inhibits the endotoxin interaction with CD14 by competition with the lipopolysaccharide-binding protein. Infect Immun 1998, 66:486-491.
29. 29 Zhang GH, Mann DM, Tsai CM: Neutralization of endotoxin in vitro and in vivo by a human lactoferrin-derived peptide. Infect Immun 1999, 67:1353-1388. The peptide LF-33 derived from lactoferrin inhibited the coagulation of limulus endotoxins with a potency comparable to polymyxin B. The first six residues of the N-terminus were critical for antiendotoxin activity. Co-injection of LF-33 with E. coli LPS significantly reduced the lethality of LPS in the galactosamine-sensitized mouse model. This peptide may have a future role for the treatment of endotoxin-induced septic shock.
30. 30 Rothman BL, Merrow M, Despins A, Kennedy T, Kreutzer DL: Effect of lipopolysaccharide on C3 and C5 production by human lung cells. J Immunol 1989, 143:196-202.
31. 31 Takabayashi T, Vannier E, Clark BD, Margolis NH, Dinarello CA, Burke JF, et al: A new biologic role for C3a and C3a desArg: regulation of TNF-alpha and IL-1 beta synthesis. J Immunol 1996, 156:3455-3460.
32. 32 Mulligan MS, Schmid E, Till GO, Hugli TE, Friedl HP, Roth RA, et al.: C5a-dependent up-regulation in vivo of lung vascular P-selectin. J Immunol 1997, 158:1857-1861.
33. 33 Brandtzaeg P: Role of J chain and secretory component in receptor-mediated glandular and hepatic transport of immunoglobulins in man. Scand J Immunol 1985, 22:111-146.
34. 34 Brandtzaeg P, Prydt H: Direct evidence for an integrated function of J chain and secretory component in epithelial transport of immunoglobulins. Nature 1984,311:71-73.
35. 35 Solari R, Kraehembuhl J-P: The biosynthesis of secretory component and its role in the transepithelial transport of IgA dimer. Meth Enzymol 1985, 6:17-20.
36. 36 Mestecky J, Russell MW, Jackson S, Brown TA: The human IgA system: A reassessment. Clin Immunol Immunopathol 1986, 40:105-114.
37. 37 Salvi S, Holgate ST: Could the airway epithelium play an important role in mucosal immunoglobulin A production? Clin Exp Allergy 1999, 29:1597-1605.
38. 38 Merrill WW, Naegel GP, Olchowski JJ, Reynolds HY: Immunoglobulin G subclass proteins in serjm and lavage fluid of normal subjects. Am Rev Respir Dis 1985, 131:584-587.
39. 39 Kaltreider HB: Phagocytic, antibody, and cell-mediated immune mechanisms. In Textbook of respiratory medicine. Edited by Murray NF, Nadel JA. Philadelphia; W.B. Saunders; 1988:332-357.
40. 40 Kaltrieder HB: Local immunity. In Immunology of the lung and upper respiratory tract. Edited by Bienstock J. New York: McGraw-Hill; 1984:191-215.
41. 41 Brain JD: Lung macrophages: how many kinds are there? What do they do? Am Rev Respir Dis 1988, 137:507-509.
42. 42 Sibille Y, Reynolds HY: Macrophages and polymorphonuclear neutrophils in lung defense and injury. Amer Rev Respir Dis 1990, 141:471-501.
43. 43 Lohmann-Matthes ML, Steinmuller C, Franke-Ullmann G: Pulmonary macrophages. Eur Resp J 1999, 7:1678-1689.
44. 44 Lehnert BE: Pulmonary and thoracic macrophage subpopulations and clearance of particles from the lung. Environ Health Perspect 1999, 97:17-46.
45. 45 Sorokin SP, Brain JD: Pathways of clearance in mouse lungs exposed to iron oxide aerosols. Anat Rec 1975, 181:581-625.
46. 46 Parra SC, Burnette R, Price HP, Takaro T: Zonal distribution of alveolar macrophages, type II pneumonocytes, and alveolar septal connective tissue gaps in adult human lungs. Amer Rev Respir Dis 1986, 133:908-912.
47. 47 Crapo JD, Barry BE, Gehr P, Bachofen M, Weibel ER: Cell number and cell characteristics of the normal human lung. Amer Rev Respir Dis 1982, 126:332-337.
48. 48 Blusse van Oud Alblas A, van der Linden-Schrever B, Van Furth R: Origin and kinetics of pulmonary macrophages during an inflammatory reaction induced by intravenous administration of heat-killed bacillus Calmette-Guerin. J Exp Med 1981, 154:235-252.
49. 49 Blusse van Oud Alblas A, Van Furth R: The origin of pulmonary macrophages. Immunobiology 1982, 161:186-192.
50. 50 Stanley ER, Chen DM, Lin HS: Induction of macrophage production and proliferation by a purified colony-stimulating factor. Nature 1999, 274:168-170.
51. 51 Chen BD, Mueller M, Chou TH: Role of granulocyte/macrophage colony-stimulating factor in the regulation of murine alveolar macrophage proliferation and differentiation. J Immunol 1988, 141:139-144.
52. 52 Fantone JC, Ward PA: Role of oxygen-derived free radicals and metabolites in leukocyte-dependent inflammatory reactions. Am J Pathol 1982, 107:395-418.
53. 53 Kemmerich B, Rossing TH, Pennington JE: Comparative oxidative microbicidal activity of human blood monocytes and alveolar macrophages and activation by recombinant gamma interferon. Am Rev Respir Dis 1987; 136:266-270.
54. 54 Goldstein IM, Roos D, Kaplan HB, Weissmann G: Complement and immunoglobulins stimulate superoxide production by human leukocytes independently of phagocytosis. J Clin Invest 1975, 56:1155-1163.
55. 55 Hoidal JR, Fox RB, LeMarbe PA, Perri R, Repine JE: Altered oxidative metabolic responses in vitro of alveolar macrophages from asymptomatic cigarette smokers. Ann Rev Respir Dis 1981, 123:85-89.
56. 56 Reynolds HY, Atkinson JP, Newball HH, Frank MM: Receptors for immunoglobulin and complement on human alveolar macrophages. J Immunol 1975, 114:1813-1819.
57. 57 Hoidal JR, Schmeling D, Peterson PK: Phagocytosis, bacterial killing, and metabolism by purified human lung phagocytes. J Infect Dis 1981, 144:61-71.
58. 58 O'Neill S, Lesperance E, Klass DJ: Rat lung lavage surfactant enhances bacterial phagocytosis and intracellular killing by alveolar macrophages. Ann Rev Respir Dis 1984, 130:225-230.
59. 59 Kelley J: Cytokines of the lung. Ann Rev Respir Dis 1990, 141:765-788.
60. 60 Kern JA, Lamb RJ, Reed JC, Elias JA, Daniele RP: Interleukin-1-beta gene expression in human monocytes and alveolar macrophages from normal subjects and patients with sarcoidosis. Am Rev Respir Dis 1988, 137:1180-1184.
61. 61 Jordana M, Richards C, Irving LB, Gauldie J: Spontaneous in vitro release of alveolar-macrophage cytokines after the intratracheal instillation of bleomycin in rats: characterization and kinetic studies. Am Rev Respir Dis 1988, 137:1135-1140.
62. 62 Panuska JR, Midulla F, Cirino NM, Villani A, Gilbert IA, McFadden ERJ, et al.: Virus-induced alterations in macrophage production of tumor necrosis factor and prostaglandin E2. Am J Physiol (Lung) 1990, 259:L396-L402.
63. 63 Assoian RK, Fleurdelys BE, Stevenson HC, Miller PJ, Madtes DK, Raines EW, et al.: Expression and secretion of type beta transforming growth factor by activated human macrophages. Proc Natl Acad Sci 1987, 84:6020-6024.
64. 64 Driscoll KE, Hassenbein DG, Carter J, Poynter J, Asquith TN, Grant RA, et al: Macrophage inflammatory proteins 1 and 2: expression by rat alveolar macrophages, fibroblasts, and epithelial cells and in rat lung after mineral dust exposure. Am J Respir Cell Mol Biol 1993, 8:311-318.
65. 65 Standiford TJ, Kunkel SL, Kasahara K, Milia MJ, Rolfe MW, Strieter RM: Interleukin-8 gene expression from human alveolar macrophages: the role of adherence. Am J Respir Cell Mol Biol 1991, 5:579-585.
66. 66 Martinet Y, Rom WN, Grotendorst GR, Martin GR, Crystal RG: Exaggerated spontaneous release of platelet-derived growth factor by alveolar macrophages from patients with idiopathic pulmonary fibrosis. N Engl J Med 1987, 317:202-209.
67. 67 Becker S, Devlin RB, Haskill JS: Differential expression of TNF, macrophage colony stimulating factor, and IL-1 by human alveolar macrophages. J Leukocyte Biol 1989, 45:353-361.
68. 68 McWilliam AS, Bilyk N, Holt PG: Macrophages amd dendritic cells in the airways. In Asthma and rhinitis. Edited by Busse WW, Holgate ST. Boston: Blackwell Scientific Publications; 1995:474.
69. 69 Rehm SR, Gross GN, Pierce AK: Early bacterial clearance from murine lungs. Species-dependent phagocyte response. J Clin Invest 1980, 66:194-199.
70. 70 Onofrio JM, Toews GB, Lipscomb MF, Pierce AK: Granulocyte-alveolarmacrophage interaction in the pulmonary clearance of Staphylococcus aureus. Am Rev Respir Dis 1983, 127:335-411.
71. 71 Gordon MY: Origin and development of neutrophils. In Immunopharmacology of neutrophits. Edited by Hellewell PG, Williams TJ. Boston: Academic Press; 1994:5.
72. 72 Williams GT: Programmed cell death: apoptosis and oncogenesis. Cell 1991, 1097-1098.
73. 73 Fanger MW, Shen L, Graziano RF, Guyre PM: Cytotoxicity mediated by human Fc receptors for IgG. Immunol Today 1989, 10:92-99.
74. 74 Henson PM, Borish LC: Neutrophil mediators in asthma. In Asthma and rhinitis. Edited by Busse WW, Holgate ST. Boston: Blackwell Scientific Publications; 1995:367.
75. 75 Henson PM, Henson JE, Fittschen C, Bratton DL, Riches DW: Degranulation and secretion by phagocytic cells. In Inflammation: basic principles and clinical correlates. Edited by Gallin JI, Goldstein IM, Snyderman R. New York: Raven Press; 1992:511.
76. 76 Newport MJ, Huxley CM, Huston S, Hawrylowicz CM, Oostra BA, Williamson R, et al.: A mutation in the interferon-gamma-receptor gene and susceptibility to mycobacterial infection. N Engl J Med 1996, 335:1941-1949.
77. 77 Rankin JA, Naegel GP, Schrader CE, Matthay RA, Reynolds HY: Air-space immunoglobulin production and levels in bronchoalveolar lavage fluid of normal subjects and patients with sarcoidosis. Am Rev Respir Dis 1983, 127:442-448.
78. 78 Israel-Assayag E, Fournier M, Cormier Y: Blockade of T cell costimulation by CTLA4-Ig inhibits lung inflammation in murine hypersensitivity pneumonitis. J Immunol 1999, 163:6794-6799. The CD28/B7 interaction provides essential costimulatory signals for T cell activation and differentiation. Alveolar macrophages from patients with hypersensitivity pneumonitis have upregulated expression of B7 molecules. The authors investigated the activity of CTLA4-Ig, a CD28/B7 antagonist, on lung inflammation in mice inoculated with Saccharopolyspora rectivirgula, compared with the group that received a control Ig. The mice that received CTLA4-Ig had markedly decreased lung inflammation, and production of proinflammatory cytokines was also increased. The study shows that blockade of CD28/B7 interactions by CTLA4-Ig may provide a novel approach to treatment of hypersensitivity pneumonitis.